JP2012521768A

JP2012521768A - 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法

抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法 Download PDF

Info

Publication number: JP2012521768A
Authority: JP; Japan
Prior art keywords: seq; vegf; antibody; cancer; binding protein
Prior art date: 2009-03-27
Legal status : Pending

Application number

JP2012502294A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012521768A5 (cg-RX-API-DMAC7.html

Inventor

パン・キ

カール・ダブリュー・バークス

パラブル・ブイ・シバクマル

Current Assignee

Zymogenetics Inc

Original Assignee

Zymogenetics Inc

Priority date

2009-03-27

Filing date

2010-03-26

Publication date

2012-09-20

2010-03-26 Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc

2012-09-20 Publication of JP2012521768A publication Critical patent/JP2012521768A/ja

2013-05-09 Publication of JP2012521768A5 publication Critical patent/JP2012521768A5/ja

Status Pending legal-status Critical Current

Links

108091008324 binding proteins Proteins 0.000 title claims abstract description 140
238000000034 method Methods 0.000 title claims description 102
102000014914 Carrier Proteins Human genes 0.000 title description 106
239000000203 mixture Substances 0.000 title description 44
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 272
230000027455 binding Effects 0.000 claims abstract description 199
206010028980 Neoplasm Diseases 0.000 claims abstract description 160
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 156
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 103
229920001184 polypeptide Polymers 0.000 claims abstract description 101
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims abstract description 82
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims abstract description 82
102000005962 receptors Human genes 0.000 claims abstract description 74
108020003175 receptors Proteins 0.000 claims abstract description 73
102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims abstract description 48
101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims abstract description 48
102100039037 Vascular endothelial growth factor A Human genes 0.000 claims abstract description 29
230000004071 biological effect Effects 0.000 claims abstract description 15
102000023732 binding proteins Human genes 0.000 claims abstract 35
108090000623 proteins and genes Proteins 0.000 claims description 133
102000004169 proteins and genes Human genes 0.000 claims description 102
108091008794 FGF receptors Proteins 0.000 claims description 93
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 91
201000011510 cancer Diseases 0.000 claims description 75
230000000694 effects Effects 0.000 claims description 50
239000013604 expression vector Substances 0.000 claims description 24
102000040430 polynucleotide Human genes 0.000 claims description 22
108091033319 polynucleotide Proteins 0.000 claims description 22
239000002157 polynucleotide Substances 0.000 claims description 22
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
206010060862 Prostate cancer Diseases 0.000 claims description 16
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 14
206010008342 Cervix carcinoma Diseases 0.000 claims description 13
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 13
201000010881 cervical cancer Diseases 0.000 claims description 13
201000007270 liver cancer Diseases 0.000 claims description 11
206010006187 Breast cancer Diseases 0.000 claims description 10
208000026310 Breast neoplasm Diseases 0.000 claims description 10
230000007423 decrease Effects 0.000 claims description 10
208000014018 liver neoplasm Diseases 0.000 claims description 9
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 8
201000005202 lung cancer Diseases 0.000 claims description 8
208000020816 lung neoplasm Diseases 0.000 claims description 8
208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
206010038389 Renal cancer Diseases 0.000 claims description 7
201000010982 kidney cancer Diseases 0.000 claims description 7
206010033128 Ovarian cancer Diseases 0.000 claims description 6
238000012258 culturing Methods 0.000 claims description 6
201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 6
208000005017 glioblastoma Diseases 0.000 claims description 6
208000018084 Bone neoplasm Diseases 0.000 claims description 3
206010073363 Acinar cell carcinoma of pancreas Diseases 0.000 claims description 2
206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
206010005949 Bone cancer Diseases 0.000 claims description 2
206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
208000000453 Skin Neoplasms Diseases 0.000 claims description 2
201000010287 pancreatic acinar cell adenocarcinoma Diseases 0.000 claims description 2
208000030352 pancreatic acinar cell carcinoma Diseases 0.000 claims description 2
201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
201000000849 skin cancer Diseases 0.000 claims description 2
201000002314 small intestine cancer Diseases 0.000 claims description 2
208000024558 digestive system cancer Diseases 0.000 claims 1
201000010231 gastrointestinal system cancer Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 65
201000010099 disease Diseases 0.000 abstract description 38
230000004614 tumor growth Effects 0.000 abstract description 7
101710146873 Receptor-binding protein Proteins 0.000 abstract description 5
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 279
210000004027 cell Anatomy 0.000 description 202
235000018102 proteins Nutrition 0.000 description 84
239000005557 antagonist Substances 0.000 description 80
125000005647 linker group Chemical group 0.000 description 74
239000012634 fragment Substances 0.000 description 70
125000003275 alpha amino acid group Chemical group 0.000 description 61
235000001014 amino acid Nutrition 0.000 description 60
108060003951 Immunoglobulin Proteins 0.000 description 56
102000018358 immunoglobulin Human genes 0.000 description 56
239000000427 antigen Substances 0.000 description 54
108091007433 antigens Proteins 0.000 description 54
102000036639 antigens Human genes 0.000 description 54
102000018233 Fibroblast Growth Factor Human genes 0.000 description 48
108050007372 Fibroblast Growth Factor Proteins 0.000 description 48
229940126864 fibroblast growth factor Drugs 0.000 description 48
108020004414 DNA Proteins 0.000 description 46
102000053602 DNA Human genes 0.000 description 46
150000001413 amino acids Chemical class 0.000 description 46
238000011282 treatment Methods 0.000 description 39
238000003752 polymerase chain reaction Methods 0.000 description 38
125000000539 amino acid group Chemical group 0.000 description 37
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 33
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 31
239000013598 vector Substances 0.000 description 31
239000002502 liposome Substances 0.000 description 30
230000033115 angiogenesis Effects 0.000 description 28
230000035772 mutation Effects 0.000 description 28
108010047041 Complementarity Determining Regions Proteins 0.000 description 27
208000035475 disorder Diseases 0.000 description 27
238000010494 dissociation reaction Methods 0.000 description 27
230000005593 dissociations Effects 0.000 description 27
230000004927 fusion Effects 0.000 description 27
102000058223 human VEGFA Human genes 0.000 description 27
201000001441 melanoma Diseases 0.000 description 27
230000004044 response Effects 0.000 description 27
230000014509 gene expression Effects 0.000 description 26
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 24
240000004808 Saccharomyces cerevisiae Species 0.000 description 24
230000003993 interaction Effects 0.000 description 24
150000007523 nucleic acids Chemical class 0.000 description 24
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 23
239000002609 medium Substances 0.000 description 23
102000039446 nucleic acids Human genes 0.000 description 23
108020004707 nucleic acids Proteins 0.000 description 23
239000013612 plasmid Substances 0.000 description 23
239000003814 drug Substances 0.000 description 22
238000006467 substitution reaction Methods 0.000 description 22
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
230000002491 angiogenic effect Effects 0.000 description 21
239000000872 buffer Substances 0.000 description 21
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 20
230000006870 function Effects 0.000 description 20
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 19
238000003556 assay Methods 0.000 description 19
239000003446 ligand Substances 0.000 description 19
238000002347 injection Methods 0.000 description 18
239000007924 injection Substances 0.000 description 18
210000001519 tissue Anatomy 0.000 description 18
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 17
238000002474 experimental method Methods 0.000 description 17
239000000243 solution Substances 0.000 description 17
208000024891 symptom Diseases 0.000 description 16
230000001225 therapeutic effect Effects 0.000 description 16
108091006020 Fc-tagged proteins Proteins 0.000 description 15
108091034117 Oligonucleotide Proteins 0.000 description 15
208000006265 Renal cell carcinoma Diseases 0.000 description 15
229940079593 drug Drugs 0.000 description 15
230000001965 increasing effect Effects 0.000 description 15
125000003729 nucleotide group Chemical group 0.000 description 15
241000588724 Escherichia coli Species 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 14
230000003472 neutralizing effect Effects 0.000 description 14
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 14
108091003079 Bovine Serum Albumin Proteins 0.000 description 13
206010009944 Colon cancer Diseases 0.000 description 13
239000002773 nucleotide Substances 0.000 description 13
102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
239000012636 effector Substances 0.000 description 12
238000012216 screening Methods 0.000 description 12
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 11
241001465754 Metazoa Species 0.000 description 11
108010076504 Protein Sorting Signals Proteins 0.000 description 11
238000005516 engineering process Methods 0.000 description 11
230000003902 lesion Effects 0.000 description 11
238000002823 phage display Methods 0.000 description 11
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 11
241001529936 Murinae Species 0.000 description 10
210000004899 c-terminal region Anatomy 0.000 description 10
238000002648 combination therapy Methods 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
239000004471 Glycine Substances 0.000 description 9
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 9
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 9
208000024770 Thyroid neoplasm Diseases 0.000 description 9
229940098773 bovine serum albumin Drugs 0.000 description 9
230000000295 complement effect Effects 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
230000012010 growth Effects 0.000 description 9
206010073071 hepatocellular carcinoma Diseases 0.000 description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
239000003550 marker Substances 0.000 description 9
208000002154 non-small cell lung carcinoma Diseases 0.000 description 9
239000008188 pellet Substances 0.000 description 9
238000000746 purification Methods 0.000 description 9
230000003248 secreting effect Effects 0.000 description 9
239000005483 tyrosine kinase inhibitor Substances 0.000 description 9
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
101000917148 Homo sapiens Fibroblast growth factor receptor 3 Proteins 0.000 description 8
101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 8
238000012408 PCR amplification Methods 0.000 description 8
210000004204 blood vessel Anatomy 0.000 description 8
229940127089 cytotoxic agent Drugs 0.000 description 8
238000012217 deletion Methods 0.000 description 8
230000037430 deletion Effects 0.000 description 8
238000012377 drug delivery Methods 0.000 description 8
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
102000055709 human FGFR3 Human genes 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
239000013641 positive control Substances 0.000 description 8
230000008569 process Effects 0.000 description 8
230000010076 replication Effects 0.000 description 8
230000019491 signal transduction Effects 0.000 description 8
230000011664 signaling Effects 0.000 description 8
238000001542 size-exclusion chromatography Methods 0.000 description 8
241000894007 species Species 0.000 description 8
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 8
241000701447 unidentified baculovirus Species 0.000 description 8
208000003174 Brain Neoplasms Diseases 0.000 description 7
208000001333 Colorectal Neoplasms Diseases 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 7
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
102000016943 Muramidase Human genes 0.000 description 7
108010014251 Muramidase Proteins 0.000 description 7
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 7
241000700159 Rattus Species 0.000 description 7
230000002159 abnormal effect Effects 0.000 description 7
239000002246 antineoplastic agent Substances 0.000 description 7
239000011324 bead Substances 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
210000003679 cervix uteri Anatomy 0.000 description 7
210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
239000003636 conditioned culture medium Substances 0.000 description 7
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
238000004520 electroporation Methods 0.000 description 7
238000009472 formulation Methods 0.000 description 7
239000000499 gel Substances 0.000 description 7
230000002163 immunogen Effects 0.000 description 7
229940072221 immunoglobulins Drugs 0.000 description 7
238000011534 incubation Methods 0.000 description 7
229960000274 lysozyme Drugs 0.000 description 7
239000004325 lysozyme Substances 0.000 description 7
235000010335 lysozyme Nutrition 0.000 description 7
239000012528 membrane Substances 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
230000037361 pathway Effects 0.000 description 7
239000000047 product Substances 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
229920002477 rna polymer Polymers 0.000 description 7
239000012679 serum free medium Substances 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
229940054269 sodium pyruvate Drugs 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
201000002510 thyroid cancer Diseases 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
206010003571 Astrocytoma Diseases 0.000 description 6
108020004705 Codon Proteins 0.000 description 6
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 6
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 6
108060001084 Luciferase Proteins 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
229920000134 Metallised film Polymers 0.000 description 6
108010029485 Protein Isoforms Proteins 0.000 description 6
102000001708 Protein Isoforms Human genes 0.000 description 6
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
150000001720 carbohydrates Chemical class 0.000 description 6
238000002512 chemotherapy Methods 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
238000007796 conventional method Methods 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
229960002897 heparin Drugs 0.000 description 6
231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
210000004408 hybridoma Anatomy 0.000 description 6
238000001597 immobilized metal affinity chromatography Methods 0.000 description 6
-1 inositol lipid Chemical class 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
210000000214 mouth Anatomy 0.000 description 6
238000006386 neutralization reaction Methods 0.000 description 6
230000026731 phosphorylation Effects 0.000 description 6
238000006366 phosphorylation reaction Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
230000005855 radiation Effects 0.000 description 6
230000009870 specific binding Effects 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
238000012546 transfer Methods 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 5
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 5
102100035290 Fibroblast growth factor 13 Human genes 0.000 description 5
229920002971 Heparan sulfate Polymers 0.000 description 5
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 5
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 5
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
206010061902 Pancreatic neoplasm Diseases 0.000 description 5
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 5
241000700605 Viruses Species 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000004913 activation Effects 0.000 description 5
239000012190 activator Substances 0.000 description 5
230000003321 amplification Effects 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
229940120638 avastin Drugs 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
244000309464 bull Species 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
238000002591 computed tomography Methods 0.000 description 5
230000006378 damage Effects 0.000 description 5
239000000539 dimer Substances 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
208000014829 head and neck neoplasm Diseases 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
210000003292 kidney cell Anatomy 0.000 description 5
238000003670 luciferase enzyme activity assay Methods 0.000 description 5
239000006166 lysate Substances 0.000 description 5
208000002780 macular degeneration Diseases 0.000 description 5
239000000463 material Substances 0.000 description 5
229960000485 methotrexate Drugs 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
210000000822 natural killer cell Anatomy 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
201000002528 pancreatic cancer Diseases 0.000 description 5
230000007170 pathology Effects 0.000 description 5
230000002085 persistent effect Effects 0.000 description 5
238000001959 radiotherapy Methods 0.000 description 5
230000006798 recombination Effects 0.000 description 5
238000005215 recombination Methods 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
230000028327 secretion Effects 0.000 description 5
206010041823 squamous cell carcinoma Diseases 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000001890 transfection Methods 0.000 description 5
238000011144 upstream manufacturing Methods 0.000 description 5
230000003442 weekly effect Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
FGTCROZDHDSNIO-UHFFFAOYSA-N 3-(4-quinolinylmethylamino)-N-[4-(trifluoromethoxy)phenyl]-2-thiophenecarboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)C1=C(NCC=2C3=CC=CC=C3N=CC=2)C=CS1 FGTCROZDHDSNIO-UHFFFAOYSA-N 0.000 description 4
HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 4
108010021064 CTLA-4 Antigen Proteins 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102400001368 Epidermal growth factor Human genes 0.000 description 4
101800003838 Epidermal growth factor Proteins 0.000 description 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
241001460678 Napo <wasp> Species 0.000 description 4
206010029113 Neovascularisation Diseases 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
108700008625 Reporter Genes Proteins 0.000 description 4
108700025832 Serum Response Element Proteins 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000009471 action Effects 0.000 description 4
238000007792 addition Methods 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
206010064930 age-related macular degeneration Diseases 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
238000010171 animal model Methods 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
208000019425 cirrhosis of liver Diseases 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
229940116977 epidermal growth factor Drugs 0.000 description 4
210000002744 extracellular matrix Anatomy 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
210000003128 head Anatomy 0.000 description 4
230000036541 health Effects 0.000 description 4
229920000669 heparin Polymers 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
239000000178 monomer Substances 0.000 description 4
239000013642 negative control Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
208000008443 pancreatic carcinoma Diseases 0.000 description 4
239000002245 particle Substances 0.000 description 4
210000001322 periplasm Anatomy 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
108060006633 protein kinase Proteins 0.000 description 4
238000001742 protein purification Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
230000009466 transformation Effects 0.000 description 4
230000001131 transforming effect Effects 0.000 description 4
230000003827 upregulation Effects 0.000 description 4
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
206010005003 Bladder cancer Diseases 0.000 description 3
ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108091029865 Exogenous DNA Proteins 0.000 description 3
108050002074 Fibroblast growth factor 17 Proteins 0.000 description 3
102100035308 Fibroblast growth factor 17 Human genes 0.000 description 3
102100037665 Fibroblast growth factor 9 Human genes 0.000 description 3
102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 3
101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 3
102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 3
206010016654 Fibrosis Diseases 0.000 description 3
206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 3
208000032612 Glial tumor Diseases 0.000 description 3
206010018338 Glioma Diseases 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
108010065805 Interleukin-12 Proteins 0.000 description 3
102000013462 Interleukin-12 Human genes 0.000 description 3
239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
102000048850 Neoplasm Genes Human genes 0.000 description 3
108700019961 Neoplasm Genes Proteins 0.000 description 3
102100028762 Neuropilin-1 Human genes 0.000 description 3
108090000772 Neuropilin-1 Proteins 0.000 description 3
241001452677 Ogataea methanolica Species 0.000 description 3
201000010133 Oligodendroglioma Diseases 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
241000256251 Spodoptera frugiperda Species 0.000 description 3
239000012505 Superdex™ Substances 0.000 description 3
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 3
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
229960000397 bevacizumab Drugs 0.000 description 3
231100000504 carcinogenesis Toxicity 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
210000004720 cerebrum Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
208000006990 cholangiocarcinoma Diseases 0.000 description 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
230000007882 cirrhosis Effects 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000010828 elution Methods 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
208000030533 eye disease Diseases 0.000 description 3
230000003325 follicular Effects 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
201000010536 head and neck cancer Diseases 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
239000007943 implant Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002452 interceptive effect Effects 0.000 description 3
230000001788 irregular Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000013507 mapping Methods 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
210000004498 neuroglial cell Anatomy 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
238000009595 pap smear Methods 0.000 description 3
210000003800 pharynx Anatomy 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
108091008598 receptor tyrosine kinases Proteins 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012552 review Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
229960003787 sorafenib Drugs 0.000 description 3
230000007480 spreading Effects 0.000 description 3
238000003892 spreading Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
230000009747 swallowing Effects 0.000 description 3
239000003104 tissue culture media Substances 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
230000014616 translation Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
201000005112 urinary bladder cancer Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108010006654 Bleomycin Proteins 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
206010006143 Brain stem glioma Diseases 0.000 description 2
206010055113 Breast cancer metastatic Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
102000014447 Complement C1q Human genes 0.000 description 2
108010078043 Complement C1q Proteins 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
101001027406 Danio rerio Fibroblast growth factor 8b Proteins 0.000 description 2
ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
101150029707 ERBB2 gene Proteins 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
206010014733 Endometrial cancer Diseases 0.000 description 2
206010014759 Endometrial neoplasm Diseases 0.000 description 2
206010014967 Ependymoma Diseases 0.000 description 2
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
241000283086 Equidae Species 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
108090000367 Fibroblast growth factor 9 Proteins 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
206010016935 Follicular thyroid cancer Diseases 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 2
208000005176 Hepatitis C Diseases 0.000 description 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
102100021866 Hepatocyte growth factor Human genes 0.000 description 2
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
102100026236 Interleukin-8 Human genes 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
108010043610 KIR Receptors Proteins 0.000 description 2
102000002698 KIR Receptors Human genes 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
241000235058 Komagataella pastoris Species 0.000 description 2
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
239000005517 L01XE01 - Imatinib Substances 0.000 description 2
239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
108010000817 Leuprolide Proteins 0.000 description 2
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
208000009018 Medullary thyroid cancer Diseases 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
206010027406 Mesothelioma Diseases 0.000 description 2
101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
102100028492 Neuropilin-2 Human genes 0.000 description 2
108090000770 Neuropilin-2 Proteins 0.000 description 2
101100293593 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nar-1 gene Proteins 0.000 description 2
208000022873 Ocular disease Diseases 0.000 description 2
239000012124 Opti-MEM Substances 0.000 description 2
206010033701 Papillary thyroid cancer Diseases 0.000 description 2
208000034038 Pathologic Neovascularization Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102100035194 Placenta growth factor Human genes 0.000 description 2
208000002151 Pleural effusion Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000006994 Precancerous Conditions Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010067787 Proteoglycans Proteins 0.000 description 2
102000016611 Proteoglycans Human genes 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
108020005091 Replication Origin Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
244000301083 Ustilago maydis Species 0.000 description 2
235000015919 Ustilago maydis Nutrition 0.000 description 2
108091008605 VEGF receptors Proteins 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
238000012436 analytical size exclusion chromatography Methods 0.000 description 2
239000003098 androgen Substances 0.000 description 2
230000003388 anti-hormonal effect Effects 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
238000002820 assay format Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008827 biological function Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
229960001561 bleomycin Drugs 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
125000000837 carbohydrate group Chemical group 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
229960005395 cetuximab Drugs 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229960000684 cytarabine Drugs 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
229920006237 degradable polymer Polymers 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
238000011033 desalting Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000005243 fluidization Methods 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
239000011888 foil Substances 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
230000033581 fucosylation Effects 0.000 description 2
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
230000002518 glial effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
239000000710 homodimer Substances 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
102000055590 human KDR Human genes 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000010354 integration Effects 0.000 description 2
229940096397 interleukin-8 Drugs 0.000 description 2
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
239000010410 layer Substances 0.000 description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
229960004338 leuprorelin Drugs 0.000 description 2
108020001756 ligand binding domains Proteins 0.000 description 2
239000007788 liquid Substances 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 2
229940076783 lucentis Drugs 0.000 description 2
201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
210000004324 lymphatic system Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000002625 monoclonal antibody therapy Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
208000007538 neurilemmoma Diseases 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
210000000963 osteoblast Anatomy 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
210000003695 paranasal sinus Anatomy 0.000 description 2
SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 2
229950010632 perifosine Drugs 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
238000003566 phosphorylation assay Methods 0.000 description 2
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
229940068977 polysorbate 20 Drugs 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
208000023958 prostate neoplasm Diseases 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
238000010791 quenching Methods 0.000 description 2
238000011552 rat model Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
210000003289 regulatory T cell Anatomy 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000003307 reticuloendothelial effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000012146 running buffer Substances 0.000 description 2
108010038196 saccharide-binding proteins Proteins 0.000 description 2
230000007017 scission Effects 0.000 description 2
229910052711 selenium Inorganic materials 0.000 description 2
239000011669 selenium Substances 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
208000000587 small cell lung carcinoma Diseases 0.000 description 2
239000008279 sol Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229960001796 sunitinib Drugs 0.000 description 2
239000013589 supplement Substances 0.000 description 2
229960001603 tamoxifen Drugs 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
206010044412 transitional cell carcinoma Diseases 0.000 description 2
238000013519 translation Methods 0.000 description 2
229960000575 trastuzumab Drugs 0.000 description 2
230000005748 tumor development Effects 0.000 description 2
230000005740 tumor formation Effects 0.000 description 2
210000003606 umbilical vein Anatomy 0.000 description 2
229960000241 vandetanib Drugs 0.000 description 2
UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000004862 vasculogenesis Effects 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
238000001262 western blot Methods 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
QDUNFIBBACFQTD-QMMMGPOBSA-N (2S)-3-(4-hydroxyphenyl)-2-nitrosopropanoic acid Chemical compound OC(=O)[C@@H](N=O)CC1=CC=C(O)C=C1 QDUNFIBBACFQTD-QMMMGPOBSA-N 0.000 description 1
WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
SRSHBZRURUNOSM-DEOSSOPVSA-N (4-chlorophenyl) (1s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(OC)=CC=C1[C@H]1C(NC=2C3=CC(Cl)=CC=2)=C3CCN1C(=O)OC1=CC=C(Cl)C=C1 SRSHBZRURUNOSM-DEOSSOPVSA-N 0.000 description 1
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
IOASODGEZSLHHY-UHFFFAOYSA-N 1-thia-4-azaspiro[4.5]decane;hydrochloride Chemical compound Cl.N1CCSC11CCCCC1 IOASODGEZSLHHY-UHFFFAOYSA-N 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
241000228431 Acremonium chrysogenum Species 0.000 description 1
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
241000589156 Agrobacterium rhizogenes Species 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
241001244729 Apalis Species 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108010002913 Asialoglycoproteins Proteins 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
239000004364 Benzylated hydrocarbon Substances 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000212384 Bifora Species 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
ZOXJGFHDIHLPTG-BJUDXGSMSA-N Boron-10 Chemical compound [10B] ZOXJGFHDIHLPTG-BJUDXGSMSA-N 0.000 description 1
WKBOTKDWSSQWDR-OIOBTWANSA-N Bromine-77 Chemical compound [77Br] WKBOTKDWSSQWDR-OIOBTWANSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
210000003771 C cell Anatomy 0.000 description 1
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000222128 Candida maltosa Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
190000008236 Carboplatin Chemical compound 0.000 description 1
206010007275 Carcinoid tumour Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
101150015280 Cel gene Proteins 0.000 description 1
206010007953 Central nervous system lymphoma Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241001227713 Chiron Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
208000037156 Choroid plexus tumor Diseases 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
206010012455 Dermatitis exfoliative Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 1
101100120663 Drosophila melanogaster fs(1)h gene Proteins 0.000 description 1
206010013952 Dysphonia Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
206010014020 Ear pain Diseases 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102400001047 Endostatin Human genes 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
108010075944 Erythropoietin Receptors Proteins 0.000 description 1
102100036509 Erythropoietin receptor Human genes 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
201000001342 Fallopian tube cancer Diseases 0.000 description 1
208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
108010000916 Fimbriae Proteins Proteins 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000021309 Germ cell tumor Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
206010018404 Glucagonoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
108010053070 Glutathione Disulfide Proteins 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
101000926713 Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 / VKM B-1768 / DS2) Dihydrofolate reductase HdrA Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
208000018565 Hemochromatosis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
108010022901 Heparin Lyase Proteins 0.000 description 1
206010019629 Hepatic adenoma Diseases 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000005331 Hepatitis D Diseases 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 1
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
108010073807 IgG Receptors Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
206010061252 Intraocular melanoma Diseases 0.000 description 1
ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
206010065630 Iris neovascularisation Diseases 0.000 description 1
244000285963 Kluyveromyces fragilis Species 0.000 description 1
235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
241001138401 Kluyveromyces lactis Species 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
238000011050 LAL assay Methods 0.000 description 1
UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
208000002404 Liver Cell Adenoma Diseases 0.000 description 1
102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
101710177649 Low affinity immunoglobulin gamma Fc region receptor III Proteins 0.000 description 1
101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
206010061269 Malignant peritoneal neoplasm Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
229930126263 Maytansine Natural products 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100381978 Mus musculus Braf gene Proteins 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
BXCOBUHTBNJJNO-UHFFFAOYSA-N N=C=S.N1C(N)=NC(=O)C2=C1N=CN2 Chemical compound N=C=S.N1C(N)=NC(=O)C2=C1N=CN2 BXCOBUHTBNJJNO-UHFFFAOYSA-N 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028836 Neck pain Diseases 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
206010029488 Nodular melanoma Diseases 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
241000320412 Ogataea angusta Species 0.000 description 1
206010068319 Oropharyngeal pain Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001715 Osteoblastoma Diseases 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
102000038030 PI3Ks Human genes 0.000 description 1
108091007960 PI3Ks Proteins 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
206010061332 Paraganglion neoplasm Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000002508 Peptide Elongation Factors Human genes 0.000 description 1
108010068204 Peptide Elongation Factors Proteins 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
206010061348 Pineal neoplasm Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
102100040682 Platelet-derived growth factor D Human genes 0.000 description 1
101710170209 Platelet-derived growth factor D Proteins 0.000 description 1
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000081 Polyestradiol phosphate Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102100038745 Protection of telomeres protein 1 Human genes 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000037323 Rare tumor Diseases 0.000 description 1
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
108010073443 Ribi adjuvant Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
208000019802 Sexually transmitted disease Diseases 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
108010068542 Somatotropin Receptors Proteins 0.000 description 1
241000519995 Stachys sylvatica Species 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
108090000054 Syndecan-2 Proteins 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
239000005463 Tandutinib Substances 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
201000000170 Thyroid lymphoma Diseases 0.000 description 1
108090000253 Thyrotropin Receptors Proteins 0.000 description 1
102100029337 Thyrotropin receptor Human genes 0.000 description 1
208000009205 Tinnitus Diseases 0.000 description 1
206010062129 Tongue neoplasm Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
241000255993 Trichoplusia ni Species 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000006593 Urologic Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
201000005969 Uveal melanoma Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
108010084455 Zeocin Proteins 0.000 description 1
241000212749 Zesius chrysomallus Species 0.000 description 1
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
208000024776 abnormal vaginal bleeding Diseases 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
108020002494 acetyltransferase Proteins 0.000 description 1
102000005421 acetyltransferase Human genes 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229910052768 actinide Inorganic materials 0.000 description 1
150000001255 actinides Chemical class 0.000 description 1
229930183665 actinomycin Natural products 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
201000005179 adrenal carcinoma Diseases 0.000 description 1
201000005188 adrenal gland cancer Diseases 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
206010002224 anaplastic astrocytoma Diseases 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
230000003140 astrocytic effect Effects 0.000 description 1
108010044540 auristatin Proteins 0.000 description 1
229960003005 axitinib Drugs 0.000 description 1
RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
201000009036 biliary tract cancer Diseases 0.000 description 1
208000020790 biliary tract neoplasm Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000008236 biological pathway Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229960003736 bosutinib Drugs 0.000 description 1
UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
238000002725 brachytherapy Methods 0.000 description 1
210000004781 brain capillary Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
LTEJRLHKIYCEOX-OCCSQVGLSA-N brivanib alaninate Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@@H](C)OC(=O)[C@H](C)N)=C1 LTEJRLHKIYCEOX-OCCSQVGLSA-N 0.000 description 1
229950005993 brivanib alaninate Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229930195731 calicheamicin Natural products 0.000 description 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
229960002412 cediranib Drugs 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000008618 cell wall macromolecule catabolic process Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
208000011654 childhood malignant neoplasm Diseases 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
208000006571 choroid plexus carcinoma Diseases 0.000 description 1
239000012501 chromatography medium Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
208000030381 cutaneous melanoma Diseases 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960002448 dasatinib Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000000447 dimerizing effect Effects 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
239000006196 drop Substances 0.000 description 1
208000007176 earache Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
230000008451 emotion Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
201000011523 endocrine gland cancer Diseases 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
238000011013 endotoxin removal Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
208000001780 epistaxis Diseases 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
229940082789 erbitux Drugs 0.000 description 1
229960005073 erlotinib hydrochloride Drugs 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960004750 estramustine phosphate Drugs 0.000 description 1
ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
101150016624 fgfr1 gene Proteins 0.000 description 1
230000003352 fibrogenic effect Effects 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
210000004905 finger nail Anatomy 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
229960005304 fludarabine phosphate Drugs 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
230000005021 gait Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229960002584 gefitinib Drugs 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
201000008822 gestational choriocarcinoma Diseases 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940080856 gleevec Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
150000008131 glucosides Chemical class 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
150000002337 glycosamines Chemical group 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
229960002913 goserelin Drugs 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
201000003911 head and neck carcinoma Diseases 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000010370 hearing loss Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
208000006359 hepatoblastoma Diseases 0.000 description 1
201000002735 hepatocellular adenoma Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
208000027498 hoarse voice Diseases 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000003026 hypopharynx Anatomy 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
238000005286 illumination Methods 0.000 description 1
229960002411 imatinib Drugs 0.000 description 1
229960003685 imatinib mesylate Drugs 0.000 description 1
YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
229940055742 indium-111 Drugs 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
229940084651 iressa Drugs 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
230000009916 joint effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
229960004891 lapatinib Drugs 0.000 description 1
WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 description 1
229950001845 lestaurtinib Drugs 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
208000002741 leukoplakia Diseases 0.000 description 1
MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
210000000088 lip Anatomy 0.000 description 1
239000008263 liquid aerosol Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
229950001750 lonafarnib Drugs 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
201000001142 lung small cell carcinoma Diseases 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
230000006674 lysosomal degradation Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
210000004995 male reproductive system Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000012913 medium supplement Substances 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
229960001786 megestrol Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
238000002493 microarray Methods 0.000 description 1
BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
229950010895 midostaurin Drugs 0.000 description 1
230000005012 migration Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000008185 minitablet Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
230000004899 motility Effects 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
FYJROXRIVQPKRY-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 FYJROXRIVQPKRY-UHFFFAOYSA-N 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
229950008835 neratinib Drugs 0.000 description 1
JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
208000023833 nerve sheath neoplasm Diseases 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229940080607 nexavar Drugs 0.000 description 1
229960001346 nilotinib Drugs 0.000 description 1
HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
229960004378 nintedanib Drugs 0.000 description 1
XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
201000000032 nodular malignant melanoma Diseases 0.000 description 1
102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
229960002700 octreotide Drugs 0.000 description 1
201000002575 ocular melanoma Diseases 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000009996 pancreatic endocrine effect Effects 0.000 description 1
208000021255 pancreatic insulinoma Diseases 0.000 description 1
238000004091 panning Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
208000007312 paraganglioma Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229960005492 pazopanib hydrochloride Drugs 0.000 description 1
MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
201000009293 penile urethral cancer Diseases 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
201000002524 peritoneal carcinoma Diseases 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229960001298 polyestradiol phosphate Drugs 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000030266 primary brain neoplasm Diseases 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
230000001023 pro-angiogenic effect Effects 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
229960003876 ranibizumab Drugs 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
239000001044 red dye Substances 0.000 description 1
230000006884 regulation of angiogenesis Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
VLQLUZFVFXYXQE-USRGLUTNSA-M rigosertib sodium Chemical compound [Na+].COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC([O-])=O)=C1 VLQLUZFVFXYXQE-USRGLUTNSA-M 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
229950009919 saracatinib Drugs 0.000 description 1
OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
230000018040 scab formation Effects 0.000 description 1
SIXSYDAISGFNSX-NJFSPNSNSA-N scandium-47 Chemical compound [47Sc] SIXSYDAISGFNSX-NJFSPNSNSA-N 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
238000010845 search algorithm Methods 0.000 description 1
238000011519 second-line treatment Methods 0.000 description 1
238000011218 seed culture Methods 0.000 description 1
JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
229950003647 semaxanib Drugs 0.000 description 1
WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
230000035807 sensation Effects 0.000 description 1
208000015891 sexual disease Diseases 0.000 description 1
238000012807 shake-flask culturing Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
230000037432 silent mutation Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
201000002074 skeletal muscle neoplasm Diseases 0.000 description 1
201000003708 skin melanoma Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000000779 smoke Substances 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
208000010485 smooth muscle tumor Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000009331 sowing Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
206010062261 spinal cord neoplasm Diseases 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
229940068117 sprycel Drugs 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
210000000242 supportive cell Anatomy 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229940034785 sutent Drugs 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
201000008753 synovium neoplasm Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
229950009893 tandutinib Drugs 0.000 description 1
229940120982 tarceva Drugs 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
HVXKQKFEHMGHSL-QKDCVEJESA-N tesevatinib Chemical compound N1=CN=C2C=C(OC[C@@H]3C[C@@H]4CN(C)C[C@@H]4C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1F HVXKQKFEHMGHSL-QKDCVEJESA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
208000013076 thyroid tumor Diseases 0.000 description 1
231100000886 tinnitus Toxicity 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
210000004906 toe nail Anatomy 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
231100000607 toxicokinetics Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000005829 trimerization reaction Methods 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
210000005233 tubule cell Anatomy 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1
229940094060 tykerb Drugs 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000037965 uterine sarcoma Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
239000004066 vascular targeting agent Substances 0.000 description 1
YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1